Ketamine (KET) antibody and antigen (hapten, BSA/OVA conjugated)

Diagnostic anti-Ketamine (KET) antibodies (anti-Ketamine, anti-KET) and diagnostic hapten-carrier conjugates BSA-Ketamine (KET), OVA-Ketamine (KET), KLH-Ketamine (KET) antigens for Pain KET detection in ELISA test, competitive ELISA, Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT.

Target products collectionGo to Pain diagnostics products collection>>


Product information

Catalog No.DescriptionUS $ Price (per mg)
GMP-SMT-234-Ag01BSA-Ketamine (KET)$756.00
GMP-SMT-234-Ag02OVA-Ketamine (KET)$756.00
GMP-SMT-234-Ab01Anti-human Ketamine (KET) mouse monoclonal antibody (mAb)$1953.00
GMP-SMT-234-Ab02Anti-human Ketamine (KET) human monoclonal antibody (mAb)$1953.00

Size: 1mg | 10mg | 100mg



Product Description

BSA-Ketamine (KET)

Cat No.GMP-SMT-234-Ag01
Product NameBSA-Ketamine (KET)
TargetKetamine (KET)
Expression platformSynthetic
Bioactivity validationKetamine (KET) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in KET level test of Pain (depression and PTSD) and related syndrome evaluation
Products descriptionCompetitive immunoassay-validated hapten-carrier conjugates BSA-Ketamine (KET) / OVA-Ketamine (KET) is Synthetic.
PurityHigh (TBD)
ApplicationCompetitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

OVA-Ketamine (KET)

Cat No.GMP-SMT-234-Ag02
Product NameOVA-Ketamine (KET)
TargetKetamine (KET)
Expression platformSynthetic
Bioactivity validationKetamine (KET) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in KET level test of Pain (depression and PTSD) and related syndrome evaluation
Products descriptionCompetitive immunoassay-validated hapten-carrier conjugates BSA-Ketamine (KET) / OVA-Ketamine (KET) is Synthetic.
PurityHigh (TBD)
ApplicationCompetitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Anti-human Ketamine (KET) mouse monoclonal antibody (mAb)

Cat No.GMP-SMT-234-Ab01
Product NameAnti-human Ketamine (KET) mouse monoclonal antibody (mAb)
TargetKetamine (KET)
Expression platformhybridoma
IsotypesMouse IgG
Bioactivity validationKetamine (KET) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Ketamine (KET) antibodies in KET level test of Pain (depression and PTSD) and related syndrome evaluation.
TagmFc
Products descriptionAnti-human Ketamine (KET) mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by hybridoma technology.
PurityHigh (TBD)
ApplicationCompetitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Anti-human Ketamine (KET) human monoclonal antibody (mAb)

Cat No.GMP-SMT-234-Ab02
Product NameAnti-human Ketamine (KET) human monoclonal antibody (mAb)
TargetKetamine (KET)
Expression platformhybridoma
IsotypesHuman IgG1
Bioactivity validationKetamine (KET) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Ketamine (KET) antibodies in KET level test of Pain (depression and PTSD) and related syndrome evaluation.
TaghFc
Products descriptionAnti-human Ketamine (KET) mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO.
PurityPurity: ≥95% (SDS-PAGE)
ApplicationCompetitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
FormulationSupplied as a 0.2 μM filtered solution of PBS, PH7.4.
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Target/Biomarker information


    1. What is Ketamine, and How Does it Relate to In Vitro Diagnosis (IVD)?

    Ketamine, chemically known as (RS)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone, is a pharmacologically diverse compound renowned for its versatile clinical applications. Principally, it is recognized for its efficacy as a dissociative anesthetic agent. Ketamine induces a unique trance-like state characterized by profound analgesia, sedation, and amnesia while preserving cardiovascular stability. Due to these distinctive properties, Ketamine is employed in a variety of medical contexts, ranging from surgical anesthesia to acute pain management and sedation during medical procedures.

    Within the realm of in vitro diagnosis (IVD), Ketamine assumes a secondary and auxiliary role. Unlike traditional diagnostic markers or analytes, Ketamine is not typically measured in IVD tests to diagnose specific medical conditions or diseases. Instead, Ketamine's significance in IVD lies in the context of patient management and surveillance during medical interventions where it is administered.

    Healthcare practitioners and anesthesiologists utilize various IVD techniques and monitoring instruments to assess a patient's vital signs, oxygen saturation levels, and other pertinent physiological parameters during Ketamine administration. These diagnostics serve the crucial purpose of upholding patient well-being and fine-tuning drug dosages to maintain the desired sedative or anesthetic effect. Consequently, Ketamine indirectly influences IVD by mandating continuous monitoring throughout its administration in clinical settings.

    2. The Importance of Monitoring Ketamine Administration

    Monitoring Ketamine itself is not a routine practice in IVD, as it is not typically used as a direct diagnostic marker for specific medical conditions. Instead, the emphasis is placed on supervising the patient's physiological responses and vital metrics during Ketamine infusion. Several pivotal reasons underscore the necessity of monitoring Ketamine administration:

    a. Safety: Ketamine is known for its potent anesthetic properties, which can induce profound sedation. Therefore, vigilant monitoring of vital signs, such as heart rate, blood pressure, respiratory rate, and oxygen saturation, is indispensable to ensure patient safety during medical procedures that involve Ketamine administration.

    b. Dosage Adjustment: Tailoring the Ketamine dosage to meet the patient's specific requirements and the demands of the medical procedure is paramount. Continuous monitoring enables real-time assessment and necessary dosage adaptations to achieve the desired level of sedation or anesthesia.

    c. Optimal Anesthesia: Maintaining the desired depth of anesthesia is critical during medical procedures. Monitoring facilitates the continuous assessment of a patient's level of sedation or anesthesia, ensuring that they remain comfortable and pain-free throughout the procedure.

    d. Adverse Reaction Detection: While Ketamine is generally considered safe, it may occasionally elicit adverse reactions or side effects in some patients. Swiftly detecting any complications, such as hallucinations, delirium, or respiratory distress, through vigilant monitoring allows for immediate intervention and mitigation of these side effects.

    e. Individualized Care: Patients exhibit varying responses to Ketamine due to factors such as age, weight, and underlying medical conditions. Monitoring empowers healthcare providers to customize treatment, optimizing the sedation or anesthesia level according to each patient's unique requirements, thereby ensuring their safety and comfort.

    In summary, while direct measurement of Ketamine is not the primary focus of IVD, monitoring Ketamine administration is pivotal. It guarantees patient safety, anesthesia optimization, and timely responses to variations or adverse reactions during medical procedures where Ketamine is employed. Continuous monitoring ensures that patients receive individualized care, enhancing the overall quality of medical interventions involving Ketamine.



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.